Skip to main content
TipRanks
Go Ultimate75% OFF

Evotec AG (EVO) AI Stock Analysis

238 Followers
EVO

Evotec AG

(NASDAQ:EVO)

Select Model
Rating:50Neutral
Price Target:$1.50â–¼(-3.85% Downside)
Action:reiterated
Date:11/07/26

The score is held back primarily by weak financial performance (ongoing losses and negative operating/free cash flow). Technicals show some near-term stabilization (price above 20/50 DMA and positive MACD) but the longer-term trend remains negative (below 100/200 DMA). The earnings call was constructive with reaffirmed guidance and cost savings progress, but liquidity decline, uneven milestone-driven profitability, and the planned 2027 manufacturing pause temper confidence. Valuation provides limited support due to negative earnings and no dividend.

Positive Factors
D&PD commercial momentumStrong D&PD sales growth, rising inbound leads, faster proposal turnaround, and customer-base expansion indicate improving commercial traction. These trends can support more reliable utilization of Evotec’s discovery platforms and strengthen its position with pharmaceutical and biotechnology partners over the next several quarters.
Negative Factors
Persistent losses and cash burnEvotec remains materially loss-making and consumes cash despite revenue growth and improved gross margin. Negative operating and free cash flow reduce internal funding capacity, increase reliance on liquidity or external financing, and constrain the company’s ability to invest while pursuing its transformation.

Evotec AG (EVO) vs. SPDR S&P 500 ETF (SPY)

-60%-40%-20%0%20%40%EVO-47.83%SPY+13.31%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$561.19M
Dividend Yield
―
Average Volume (3M)
106.85K
Price to Earnings (P/E)
-2.9
Beta (1Y)
1.10
Revenue Growth
0.31%
EPS Growth
-19.37%
Country
US
Employees
4,553
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Evotec AG Business Overview & Revenue Model

Company Description

Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broa...

Evotec AG Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q3-2026)|% Change Since:-0.64%|Next Earnings Date:May 11, 2022
Earnings Call SentimentPositive

The call was predominantly positive. Q3 performance improved materially, D&PD commercial indicators strengthened, Horizon savings were ahead of plan, the Vertex commercial-manufacturing selection advanced JEB, and full-year guidance was reaffirmed with expectations toward the upper end of the ranges. These positives outweighed the weaker nine-month revenue and EBITDA results, lower liquidity, delayed revenue conversion, lower expected Q4 milestones, and the planned 2027 manufacturing pause.

Positive Updates

Q3 Revenue Stabilized and EBITDA Approached Break-Even
Q3 2026 group revenue was EUR 164.9 million, broadly stable versus EUR 163.9 million in Q3 2025. Adjusted group EBITDA improved to negative EUR 1.6 million from negative EUR 15 million, bringing the group close to break-even, supported by stronger D&PD and JEB performance and a lower cost base.

Negative Updates

Nine-Month Group Revenue Declined
First-nine-month group revenue totaled EUR 465 million, down 13.1% from EUR 535.1 million in the prior-year period. At constant exchange rates, revenue declined 10.8% to EUR 477.4 million, reflecting the weaker first half, slower D&PD sales-to-revenue conversion, delayed JEB program activities, and the EUR 25 million Sandoz license sale recognized in Q1 2025.

Company Guidance

For full year 2026, Evotec reaffirmed group revenues of EUR 570 million-EUR 610 million on a reported basis and EUR 595 million-EUR 635 million at constant exchange rates, with adjusted group EBITDA between minus EUR 105 million and minus EUR 70 million, or between minus EUR 90 million and minus EUR 60 million at constant exchange rates; based on current visibility, both revenue and adjusted EBITDA are expected to finish toward the upper end of their respective guidance ranges. Horizon targets approximately EUR 75 million in run rate savings by the end of 2027, with 20%-30% planned for 2026 and more than 20% already delivered by the end of September. By 2030, Evotec’s ambition is around EUR 1 billion in group revenues, with an adjusted EBITDA margin of 20% by the end of 2028 and above 20% by the end of 2030; the framework comprises around 40% D&PD base business, another 20% D&PD strategic partnerships, and approximately 40% JEB, with D&PD base revenues expected to reach approximately EUR 400 million at a CAGR of around 10%, strategic partnerships approximately EUR 200 million at a CAGR of around 5%, and JEB approximately EUR 400 million at a CAGR of around 20%.

Evotec AG Financial Statement Overview

Summary

Despite +14.4% TTM revenue growth and an improved gross margin (13.2% vs 8.3% in 2025), profitability and cash generation are weak: EBIT margin is -14.0%, net margin is -25.2%, and both operating cash flow (~-95M) and free cash flow (~-131M) are negative. The balance sheet is only moderately supportive (debt-to-equity ~0.65), but losses and negative ROE (~-26%) reduce financial flexibility.

Income Statement

28Negative

Balance Sheet

58Neutral

Cash Flow

24Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Dec 2022Mar 2022
Income Statement
Total Revenue720.90M757.26M796.97M781.43M751.45M618.03M
Gross Profit94.32M62.66M114.88M175.05M174.06M151.54M
EBITDA-85.84M-13.89M-80.66M24.13M-57.61M316.63M
Net Income-183.62M-99.43M-196.08M-83.91M-175.66M215.51M
Balance Sheet
Total Assets1.50B1.78B1.91B2.25B2.26B2.24B
Cash, Cash Equivalents and Short-Term Investments418.48M476.19M396.80M604.11M707.31M858.50M
Total Debt0447.50M443.54M815.35M506.67M512.92M
Total Liabilities863.31M964.64M959.98M1.13B1.07B857.48M
Stockholders Equity641.66M813.36M952.52M1.12B1.19B1.38B
Cash Flow
Free Cash Flow-131.32M-78.74M-114.02M-179.56M24.46M3.29M
Operating Cash Flow-95.29M-9.06M18.22M36.44M205.81M122.24M
Investing Cash Flow224.14M159.86M-71.19M-13.29M-412.80M-243.85M
Financing Cash Flow-16.76M-30.93M-161.42M71.96M-58.15M398.43M

Evotec AG Technical Analysis

Technical Analysis SentimentNegative
Last Price1.56

Price Trends

50DMA1.60Negative
100DMA1.88Negative
200DMA2.42Negative

Market Momentum

MACD0.02Negative
RSI47.81Neutral
STOCH42.21Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EVO, the sentiment is Negative. The current price of 1.56 is below the 20-day moving average (MA) of 1.59, below the 50-day MA of 1.60, and below the 200-day MA of 2.42, indicating a bearish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 47.81 is Neutral, neither overbought nor oversold. The STOCH value of 42.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EVO.

Evotec AG Risk Analysis

Evotec AG disclosed 10 risk factors in its most recent earnings report. Evotec AG reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Evotec AG Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

EVO against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
RDYRDY68Neutral$12.18B41.077.37%0.57%-10.52%-55.45%
ALKSALKS67Neutral$7.90B15676.67-0.02%―15.27%-100.08%
TKNOTKNO56Neutral$516.43M-27.83-24.95%―15.45%12.64%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
LFCRLFCR50Neutral$243.36M-3.40381.59%―――
EVOEVO50Neutral$580.81M-2.91-25.63%―0.31%-19.37%
HCMHCM49Neutral$2.59B160.411.43%―-8.81%-96.21%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%EVOALKSRDYLFCRHCMTKNODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
EVO and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
EVOEvotec Ag (Adr)1.56-1.40-47.30%
ALKSAlkermes plc46.5317.2759.02%
RDYDr. Reddy's Laboratories Ltd14.700.765.43%
LFCRLifecore Biomedical, Inc.6.42-1.18-15.59%
HCMHutchmed (China) Limited14.730.070.48%
TKNOAlpha Teknova, Inc.7.773.3676.19%

Evotec AG Corporate Events

Evotec Reports Nine-Month 2026 Results, Highlights Transformation and Pipeline Progress

Nov 5, 2026

Evotec SE is a drug-discovery and development company providing research, development and biologics manufacturing services, with a market focus on pharmaceutical and biotechnology partners in areas including immunology, oncology and infectious diseas...

Evotec Names Joanna Holbrook Chief Scientific Officer as Investor Holdings Shift

Oct 15, 2026

On October 15, 2026, Evotec SE announced the appointment of Dr. Joanna Holbrook as Chief Scientific Officer and member of the Management Board, effective November 1, 2026. Holbrook, a seasoned R&D leader with more than 25 years of experience across p...

Evotec SE Nine-Month 2026 Results Beat Expectations as Full-Year Guidance Reaffirmed

Oct 14, 2026

Evotec SE, a Hamburg-based biopharmaceutical drug discovery and development specialist, reported preliminary unaudited figures for the first nine months of 2026 that outperformed market expectations. The company derives its revenues from partnering w...

Evotec SE Announces Chief Scientific Officer Transition as Long-Serving CSO Steps Down

Sep 29, 2026

Evotec SE, a Hamburg-based life science company listed on Nasdaq and Frankfurt, specialises in AI-enhanced drug discovery and development across small molecules, biologics and cell therapies. With proprietary technology platforms and a network that i...

Evotec’s Just – Evotec Biologics Starts Phase 1 Trial of Orthopoxvirus Antibodies for U.S. Biodefense

Sep 9, 2026

Evotec SE announced on September 9, 2026, that its CDMO subsidiary Just – Evotec Biologics has initiated a first-in-human Phase 1 clinical trial of JST-018, a monoclonal antibody cocktail targeting orthopoxviruses, under the U.S. Department of War’s...

Evotec SE Posts Weaker Half-Year 2026 Results but Presses Ahead With ‘Horizon’ Transformation and Biologics Push

Aug 13, 2026

On 13 August 2026, Evotec SE released its half-year 2026 interim report, showing that group revenues fell 19.2% year-on-year to €300.1 million and adjusted EBITDA deteriorated to a loss of €42.7 million amid weak conversion of sales to revenue and ch...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 07, 2026